NDAORALCAPSULE, PELLETS
Approved
Sep 2023
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
51
Data completeness
5/8 — Partial
XALKORI (crizotinib) by Pfizer is cytochrome p450 3a inhibitors [moa]. First approved in 2023.
Drug data last refreshed 13h ago · AI intelligence enriched 18h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XALKORI (crizotinib) is an oral small-molecule kinase inhibitor and cytochrome P450 3A inhibitor used to treat ALK-positive and ROS1-positive non-small cell lung cancer. It works by blocking aberrant kinase signaling that drives tumor growth in patients with specific molecular alterations.
$0.052BPart D
PeakStable
3.1 years to LOEPeak-stage asset with modest Medicare claims volume; growth opportunities likely depend on indication expansion and patient identification improvements.
Mechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (51)
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Started Sep 2026
450 enrolled
Uveal Melanoma
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Started Dec 2023
190 enrolled
Carcinoma, Non-Small-Cell Lung
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Started Oct 2023
420 enrolled
Metastatic Uveal Melanoma
Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC
Started Dec 2021
275 enrolled
Non-Small Cell Lung CancerALK-positiveSAF-189s
Crizotinib Continuation Clinical Study
Started Dec 2021
27 enrolled
NSCLCALCLIMT
Worked on XALKORI at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.